Arrowhead Research Names General Counsel

Pasadena-based Arrowhead Research, which is developing targeted RNAi biopharmaceuticals, said late Thursday that it has named Patrick O'Brien as the company's new General Counsel. O'Brien had most recently been Group Vice President, Legal, for Shire, and also had served at Johnson & Johnson, at the U.S. Food and Drug Administration, and in private practice.